Zinema Media Shareholders Approve Rs 2.50 Cr Preferential Issue and Key Resolutions at 42nd AGM
Zinema Media and Entertainment Limited announced the voting results for its 42nd AGM held on September 30, 2026, where all resolutions passed with 100% of votes in favour. Key approvals include the issuance of up to 24,99,000 equity shares at par (Rs 10 each) aggregating to Rs 2,49,90,000 on a preferential basis to non-promoter allottees under an NCLT order. This equity infusion represents approximately 22.7% of the company's current market capitalization of Rs 11 crore. Shareholders also approved borrowing limits under Section 180(1)(c) and the re-appointment of Managing Director Baskaran Sathya Prakash.
உச்சம் நம்பிக்கை
என்ன மாறியதுShareholders formally approved a Rs 2.50 crore preferential equity allotment at par pursuant to an NCLT order, along with expanded borrowing powers.
ஏன் இது முக்கியம்The Rs 2.50 crore issuance injects fresh equity equal to ~22.7% of its current market cap, which increases the share base by ~35% while diluting existing holders, but provides growth capital to a micro-cap firm.
Preferential issue size: INR 2,49,90,000Issue price per share: INR 10/-Equity shares to be allotted: 24,99,000Fundraise vs Market Cap: ~22.7%Total votes polled: 28,06,500
📅 குறுகிய காலம்Routine execution of AGM business; investors will monitor corporate filings for the final allotment date and listing approvals for the new shares.
📈 நீண்ட காலம்The issue increases the equity base and aids debt servicing/working capital, but issues new shares at par (Rs 10) against a prevailing market price of ~Rs 16.1, leading to equity dilution.
⚠ அபாய எச்சரிக்கைகள்
- Equity dilution of ~35% on total share count
- Shares issued at Rs 10 per share, at a discount to the current trading price of Rs 16.1
- Relatively low public voting participation (23.48% polled among non-promoter holders)
👀 கவனிக்க வேண்டியவை
Track the formal allotment of the 24,99,000 shares, subsequent equity dilution, and the exact deployment timeline of the Rs 2.50 crore capital infusion.
